Research Reports

Summary

Aquestive Therapeutics entered into a $150 million five-year debt facility with Oaktree, refinancing $45 million of existing indebtedness and securing tiered tranches tied to FDA approval of Anaphylm and sales milestones, while reporting Q1 2026 revenue growth of 66% to $14.4 million and narrowing net loss to $8.1 million.

Key takeaways

Entered $150M five-year term loan facility with Oaktree: $55M funded at closing, $20M contingent on FDA approval of Anaphylm by June 30, 2027, $25M on net sales milestone by Dec 31, 2027, and up to $50M by mutual consent — materially extending cash runway and deferring principal repayment until maturity in 2031.

Repaid $45.0M outstanding principal under prior Indenture with U.S. Bank Trust Company, terminating that agreement and associated security interests; incurred prepayment and final payment fees but no penalties.

Q1 2026 revenue rose 66% year-over-year to $14.4M driven by $4.6M increase in license/royalty revenue (mainly from Zevra) and $1.6M increase in manufacturing revenue (primarily Suboxone), supporting improved near-term liquidity.

Net loss narrowed to $8.1M ($0.07 per share) from $22.9M ($0.24 per share) in Q1 2025 due to lower SG&A (−$8.1M, including $4.3M PDUFA fee reversal) and R&D (−$1.2M), partially offset by lower interest income.

Reaffirmed full-year 2026 guidance: $46–$50M total revenue and Non-GAAP adjusted EBITDA loss of $35–$30M; ended Q1 with $110.7M cash and cash equivalents.

Issued warrants to Oaktree Lenders: 1.75% of each tranche’s principal amount, priced at Tranche A’s 30-day VWAP (for Tranche A) or lower of Tranche A VWAP or subsequent tranche’s VWAP (for Tranches B/C), exercisable for five years.

Full analysis

This 8-K represents a pivotal financial and strategic inflection point for Aquestive: it simultaneously resolves near-term liquidity pressure, de-risks the Anaphylm regulatory pathway, and strengthens the balance sheet ahead of potential commercialization. The $150M Oaktree facility replaces $45M of costly, maturing debt — eliminating $45M in principal repayments over three years and deferring all principal until 2031 — while embedding milestone-based capital access that directly aligns lender incentives with key value inflection points: FDA approval (Tranche B), commercial traction (Tranche C), and strategic optionality (Tranche D). Critically, the covenant structure is investor-friendly: the Minimum Net Sales test only activates post-Tranche B funding and includes robust waivers tied to cash coverage (150% of loan balance) or market cap ($500M), reducing near-term execution risk. Financially, Q1 2026 results confirm operational progress: revenue grew 66% YoY to $14.4M, driven by strong licensing (Zevra royalties) and stable manufacturing (Suboxone), while SG&A dropped $8.1M YoY — largely reversing the one-time $4.3M PDUFA fee from Q1 2025 — and R&D declined $1.2M as Anaphylm trial costs eased pending new study initiation. The $110.7M cash position provides ~18 months of runway at current burn, comfortably covering the planned human factors and PK studies needed for the Q3 2026 NDA resubmission. With the RTW strategic funding agreement extended to June 2027 and this debt facility in place, Aquestive now expects $150M in total available capital for Anaphylm launch — a decisive step toward derisking commercial readiness and validating the company’s ability to execute its dual-path strategy of near-term revenue generation and long-term pipeline value creation via AdrenaVerse.